肺移植术后的免疫抑制剂应用进展  

Immunosuppression regimens development following lung transplantation

作　　者：崔向丽[1] 宫丽丽[1] 胡滨[2] 游宾[2] 陈其瑞[2] 张文谦[2] 刘丽宏[1] 李辉[2] 

机构地区：[1] 首都医科大学附属北京朝阳医院药事部,100020 [2] 首都医科大学附属北京朝阳医院胸外科,100020

出　　处：《国际呼吸杂志》2016年第3期228-232,共5页International Journal of Respiration

基　　金：国家自然科学基金（81302822）

摘　　要：肺移植是肺脏疾病终末期的治疗选择，闭塞性细支气管炎、巨细胞病毒感染都是移植后第1年常见的慢性排斥反应。所有的肺移植患者终生服用3种免疫抑制药物，包括钙调神经磷酸酶抑制剂、抗代谢药物及小剂量激素。不同的医疗机构使用的免疫抑制剂的方案存在差异，肺移植使用免疫抑制剂的共识尚未形成。本综述主要探讨肺移植术后诱导和维持免疫抑制治疗药物与方案，为规范治疗提供参考。Lung transplantation is the ultimate treatment option for patients with end-stage lung disease.Chronic rejection,in the form of bronchiolitis obliterans syndrome,and noncytomegalovirus infections are the major causes of morbidity and mortality beyond the flrst year after transplantation.Most lung transplant recipients are treated lifelong with a three-drug immunosuppression regimen consisting of a calcineurin inhibitor,an antimetabolite,and low-dose corticosteroids.However,induction and maintenance immunosuppression strategies vary widely between centers,and a consensus on the ideal management of this patient population remains elusive.This review discusses induction and maintenance immunosuppression agents and regimens following lung transplantation to guide therapy.

关 键 词：肺移植 免疫抑制剂 环孢素 他克莫司 

分 类 号：R655.3[医药卫生—外科学]